Summary Box: FDA expands approval of J&J drug

Published



WASHINGTON (AP) — FDA OK: The Food and Drug Administration on Monday approved the drug Zytiga for a new group of prostate cancer patients who have not yet received chemotherapy.

FAMILIAR FACE: The FDA previously approved the pill from Johnson & Johnson for men with prostate cancer who have already taken the chemotherapy drug docetaxel.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.